Basic, Translational and Clinical Pharmacy Research

The Basic, Translational and Clinical Pharmacy Research group focuses on personalized medicine, and is involved in various lines of research including the study of the chemical-functional stability of drugs, as well as pharmacokinetics and pharmacogenetics. We also evaluate the safety, efficacy and cost of innovative drugs, and explore mobile health and telemedicine. The group has a strong interdisciplinary research potential and values collaboration, actively engaging in collaborative projects with other groups to broaden its scope. In 2023, the group consists of 36 members and has produced 31 publications, 9 of which are in the top quartile. We aim to generate new knowledge in order to improve efficacy and safety of pharmacological treatments. Our clinical expertise allows us to identify the needs and evidence gaps, as well as analyze relevant real-world data in the clinical setting. As a result, this enables us to draw conclusions directly applicable to clinical practice.

eCORE

Advanced Therapies and Advanced Interventions, Nanomedicine, Transplant & Donation
Personalized Medicine, Innovative Diagnostics, Molecular Imaging & Digital Health

Team

Group Leader
Maria Queralt Gorgas Torner, Marta Miarons Font

Principal Investigator (PI)
Maria Queralt Gorgas Torner, Marta Miarons Font, David Berlana Martín, José Bruno Montoro Ronsano

Researchers
Carla Alonso Martínez, Danae Anguita Domingo, Angel Arévalo Bernabé, Maria Josep Cabañas Poy, Maria Josep Carreras Soler, Susana Clemente Bautista, José Manuel del Río Gutiérrez, Laura Doménech Moral, Héctor Carlos García Diaz, Laura Gómez Ganda, Javier Gómez Alonso, Maria Rosa Gómez Domingo, Ariadna Gracia Moya, Maria Blanca Guembe Zabaleta, María Guerra Gonzalez, Inés Jiménez Lozano, Juan Carlos Juárez Giménez, Patricia Marrero Álvarez, María Eugenia Palacio Lacambra, Alba Pau Parra, Adrián Puertas Sanjuan, Berta Renedo Miró, Javier Santander Reboreda, Maria del Carmen Torres Moreno, Emili Vallvé Alcón, Pau Vancells Lujan, Jana Vidal Otero

PhD Students
Ignasi Cardona Pascual, Sonia García García, María Larrosa García, Carlos Javier Parramón Teixidó, Javier Varela González-Aller

Publications

38.1

%Q1

91.70

Impact Factor

4.37

Average Impact Factor

Miarons M, Manzaneque-Gordón A, Riera P, Gutiérrez-Nicolás F; RedDPYD Research Group with the Spanish Society of Hospital Pharmacy (SEFH)
Allelic Frequency of DPYD Genetic Variants in Patients With Cancer in Spain: The PhotoDPYD Study
Oncologist. 2023 May 8;28(5):e304-e308.
DOI: 10.1093/oncolo/oyad077
IF: 5.8

Pérez-Robles R, Salmerón-García A, Hermosilla J, Torrente-López A, Clemente-Bautista S, Jiménez-Lozano I, Cabañas-Poy MJ, Cabeza J, Navas N
Comprehensive physicochemical characterization of a peptide-based medicine: Teduglutide (Revestive®) structural description and stress testing
European Journal of Pharmaceutics and Biopharmaceutics. 2023 Mar;184:103-115.
DOI: 10.1016/j.ejpb.2023.01.001
IF: 4.9

Fernández-Ledesma B, Mendoza-Palomar N, Melendo-Pérez S, Fernández-Polo A, Renedo-Miró B, Pau-Parra A, Luque-Pardos S, Grau-Cerrato S, Vima-Bofarull J, Martín-Gómez MT, Pujol-Jover M, Benítez-Carbante MI, Díaz de Heredia C, Soler-Palacin P
Isavuconazole use and TDM in real-world pediatric practice
Antimicrobial Agents and Chemotherapy. 2023 Dec 14;67(12):e0082923.
DOI: 10.1128/aac.00829-23
IF: 4.9

Colom H, Blasi A, Montoro B, Arévalo AG, Cendrós JM, Sabaté A
Population pharmacokinetic modelling of fibrinogen in patients with congenital or acquired-chronic or acute-hypofibrinogenaemia
British Journal of Clinical Pharmacology. 2023 Sep;89(9):2703-2713.
DOI: 10.1111/bcp.15741
IF: 3.4

Carreras MJ, Tomás-Guillén E, Farriols A, Renedo-Miró B, Valdivia C, Vidal J, Saura C, Carles J, Felip E, Gorgas MQ, Tabernero J, Monterde J
Use of Drugs in Clinical Practice and the Associated Cost of Cancer Treatment in Adult Patients with Solid Tumors: A 10-Year Retrospective Cohort Study
Current Oncology. 2023 Aug 30;30(9):7984-8004.
DOI: 10.3390/curroncol30090580
IF: 2.6

Projects

Análisis nacional de la multimorbilidad y complejidad terapéutica en receptores de trasplante de órgano sólido
Principal Investigator: Susana Clemente Bautista
Agency: Sociedad Española de Farmacia Hospitalaria (SEFH)
Funding: No funding
Period: 2022-2025

Farmacocinética de ceftazidima-avibactam en pacientes críticos en terapia soporte con oxigenación con membrana extracorpórea
Principal Investigator: Laura Doménech Moral
Agency: Sociedad Española de Farmacia Hospitalaria (SEFH)
Funding: 8,631.00€
Period: 2022-2024

Caracterización de la farmacocinética de rituximab en pacientes con enfermedades renales con afectación glomerular primaria
Principal Investigator: María Larrosa García
Agency: Societat Catalana de Farmàcia Clínica (SCFC)
Funding: 12,000.00€
Period: 2020-2024

Análisis de utilización de células madre mesenquimales para el tratamiento de complicaciones post-alotrasplante de progenitores hematopoyéticos en hospitales españoles
Principal Investigator: Carla Alonso Martínez
Agency: Fundación Española de Farmacia Hospitalaria (FEFH) / Sociedad Española de Farmacia Hospitalaria (SEFH)
Funding: 6,000.00€
Period: 2021-2025

Herramienta de soporte a la decisión para la estratificación de pacientes con COVID-19 según características sociodemográficas, clínicas y de tratamiento habitual mediante inteligencia artificial
Principal Investigator: Marta Miarons Font
Agency: Sociedad Española de Farmacia Hospitalaria (SEFH)
Funding: 4,420.00€
Period: 2022-2024